EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study

Jack Stone, Katharine Jane Looker, Romain Silhol, Katherine Mary Elizabeth Turner, Richard Hayes, Jenny Coetzee, Stefan Baral, Sheree Schwartz, Philippe Mayaud, Sami Gottlieb, Marie-Claude Boily, Peter Vickerman

eBioMedicine · 2023

DOI: 10.1016/j.ebiom.2023.104530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eBioMedicine, 2023. Verfasst von Jack Stone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: jack.stone@bristol.ac.uk. Hauptthemen laut MEDLINE: Herpes Genitalis, HIV Infections, Peptic Ulcer. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Medical Research Council, University of Cape Town.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence suggests HSV-2 infection increases HIV acquisition risk and HIV/HSV-2 coinfection increases transmission risk of both infections. We analysed the potential impact of HSV-2 vaccination in South Africa, a high HIV/HSV-2 prevalence setting. METHODS: We adapted a dynamic HIV transmission model for South Africa to incorporate HSV-2, including synergistic effects with HIV, to evaluate the impact of: (i) cohort vaccination of 9-year-olds with a prophylactic vaccine that reduces HSV-2 susceptibility; (ii) vaccination of symptomatically HSV-2-infected individuals with a therapeutic vaccine that reduces HSV shedding. FINDINGS: An 80% efficacious prophylactic vaccine offering lifetime protection with 80% uptake could reduce HSV-2 and HIV incidence by 84.1% (95% Credibility Interval: 81.2-86.0) and 65.4% (56.5-71.6) after 40 years, respectively. This reduces to 57.4% (53.6-60.7) and 42.1% (34.1-48.1) if efficacy is 50%, 56.1% (53.4-58.3) and 41.5% (34.2-46.9) if uptake is 40%, and 29.4% (26.0-31.9) and 24.4% (19.0-28.7) if protection lasts 10 years. An 80% efficacious therapeutic vaccine offering lifetime protection with 40% coverage among symptomatic individuals could reduce HSV-2 and HIV incidence by 29.6% (21.8-40.9) and 26.4% (18.5-23.2) after 40 years, respectively. This reduces to 18.8% (13.7-26.4) and 16.9% (11.7-25.3) if efficacy is 50%, 9.7% (7.0-14.0) and 8.6% (5.8-13.4) if coverage is 20%, and 5.4% (3.8-8.0) and 5.5% (3.7-8.6) if protection lasts 2 years. INTERPRETATION: Prophylactic and therapeutic vaccines offer promising approaches for reducing HSV-2 burden and could have important impact on HIV in South Africa and other high prevalence settings. FUNDING: WHO, NIAID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes GenitalisHIV InfectionsPeptic UlcerHumansHerpesvirus 2, HumanUlcerSouth AfricaIncidenceVaccinationGenitalia

Stichwörter der Autor:innen

HIVHSV-2Mathematical modellingSouth AfricaVaccine

Autor:innen und Institutionen

  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: jack.stone@bristol.ac.uk.
  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
  • Bristol Veterinary School, University of Bristol, Bristol, UK.
  • Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa.

Förderung

  • World Health Organization
  • Medical Research Council
  • University of Cape Town
  • Office of AIDS Research
  • Joint United Nations Programme on HIV/AIDS
  • University of Washington
  • Foreign, Commonwealth and Development Office
  • Johns Hopkins University

Zitieren

APA

Stone, J., Looker, K. J., Silhol, R., Turner, K. M. E., Hayes, R., Coetzee, J., Baral, S., Schwartz, S., Mayaud, P., Gottlieb, S., Boily, M. C., & Vickerman, P. (2023). The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104530

Vancouver

Stone J, Looker KJ, Silhol R, Turner KME, Hayes R, Coetzee J, et al. The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study. eBioMedicine. 2023. doi:10.1016/j.ebiom.2023.104530

BibTeX
@article{Stone2023,
  author = {Stone, Jack and Looker, Katharine Jane and Silhol, Romain and Turner, Katherine Mary Elizabeth and Hayes, Richard and Coetzee, Jenny and Baral, Stefan and Schwartz, Sheree and Mayaud, Philippe and Gottlieb, Sami and Boily, Marie-Claude and Vickerman, Peter},
  title = {The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study},
  journal = {eBioMedicine},
  year = {2023},
  doi = {10.1016/j.ebiom.2023.104530}
}
Kostenlos starten →